Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9591MR)

This product GTTS-WQ9591MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9591MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10101MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ1264MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ5873MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ6862MR IVTScrip™ mRNA-Anti-KLKB1, DX-2930(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DX-2930
GTTS-WQ8770MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ4234MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIIB029
GTTS-WQ8235MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ9824MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA JS004
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW